CompletedPhase 2NCT01168232
Ixabepilone in Treating Patients With Recurrent or Persistent Uterine Cancer
Studying Carcinosarcoma of the corpus uteri
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- National Cancer Institute (NCI)
- Principal Investigator
- Carolyn McCourt, MDNRG Oncology
- Intervention
- Ixabepilone(drug)
- Enrollment
- 42 enrolled
- Eligibility
- 18 years · FEMALE
- Timeline
- 2010 – 2013
Study locations (30)
- University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
- John Muir Medical Center-Concord Campus, Concord, California, United States
- John Muir Medical Center-Walnut Creek, Walnut Creek, California, United States
- University of Colorado Hospital, Aurora, Colorado, United States
- Hartford Hospital, Hartford, Connecticut, United States
- Smilow Cancer Hospital Care Center at Saint Francis, Hartford, Connecticut, United States
- The Hospital of Central Connecticut, New Britain, Connecticut, United States
- Florida Hospital Orlando, Orlando, Florida, United States
- Memorial University Medical Center, Savannah, Georgia, United States
- Saint Alphonsus Cancer Care Center-Boise, Boise, Idaho, United States
- Rush University Medical Center, Chicago, Illinois, United States
- University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States
- Sudarshan K Sharma MD Limted-Gynecologic Oncology, Hinsdale, Illinois, United States
- Good Samaritan Regional Health Center, Mount Vernon, Illinois, United States
- Northwestern Medicine Cancer Center Warrenville, Warrenville, Illinois, United States
- +15 more locations on ClinicalTrials.gov
Collaborators
NRG Oncology
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT01168232 on ClinicalTrials.govOther trials for Carcinosarcoma of the corpus uteri
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT07029399A Study With NKT5097 for Adults With Advanced/Metastatic Solid TumorsNiKang Therapeutics, Inc.
- RECRUITINGPHASE2NCT05619913EPOCH: Eribulin and Pembrolizumab in Ovarian/Uterine CarcinosarcomaAustralia New Zealand Gynaecological Oncology Group
- ACTIVE NOT RECRUITINGPHASE2NCT05147558A Study of Pembrolizumab With Lenvatinib in Women With Advanced Uterine CarcinosarcomaMemorial Sloan Kettering Cancer Center
- RECRUITINGPHASE1, PHASE2NCT03686124ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid TumorsImmatics US, Inc.